Clinical Trial Update: Study of CP-690,550 Versus Placebo In Rheumatoid Arthritis Patients On Background Methotrexate With Inadequate Response To Tumor Necrosis Factor (TNF) Inhibitors [Phase 3]

View source ↗

Summary

Phase 3 trial of CP-690,550 (tofacitinib) vs placebo in rheumatoid arthritis patients with inadequate response to TNF inhibitors on background methotrexate; stu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• CP-690,550 (tofacitinib)

Snippet

Sponsor: Pfizer | Conditions: Arthritis, Rheumatoid | Phase 3 | Status: COMPLETED | Results posted: 2013-01-10